<DOC>
	<DOCNO>NCT00613470</DOCNO>
	<brief_summary>This study one component large U01 grant submit August , 2004 NIGMS part Pharmacogenomic Research Network . This study enroll 1200 patient 4 year . It know functionally significant genetic polymorphism cytochrome P450 ( CYPs ) contribute individual difference response specific selective serotonin reuptake inhibitor ( SSRIs ) . However , good understand pharmacogenomics PK PD SSRI antidepressant inform clinical practice . Therefore , propose evaluate contribution pharmacogenomics variation response highly specific SSRIs citalopram ( racemic mixture ) escitalopram ( chiral compound contain active S-isomer citalopram ) correlate PK PD variation agent intragene haplotype gene encode protein involve citalopram metabolism , well central nervous system ( CNS ) pathways monoamine neurotransmitter biosynthesis , metabolism , storage , release , reuptake , receptor . In future `` candidate pathway '' intragene haplotype genotyping strategy also complement application genome-wide screen perform DNA subject extreme phenotype response citalopram . Phenotypes measure initiation citalopram escitalopram therapy include determination serum citalopram metabolite concentration , treatment response measure Hamilton Rating Scale Depression index , number severity side effect determine structured questionnaire . The hypothesis test inherited variation citalopram metabolism transport ( PK ) and/or PD variation result inherit variation monoamine neurotransmitter biosynthesis , metabolism , reuptake , storage , receptor signal contribute individual variation citalopram antidepressant efficacy and/or side effect .</brief_summary>
	<brief_title>Pharmacodynamics Pharmacokinetics Citalopram Escitalopram</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>1 . Outpatients inpatient nonpsychotic MDD . 2 . A score &gt; 14 HRSD17 ( equivalent 10 great PHQ9 use primary care assess depression ) give medication exceeds effect placebo primary care participant HRSD17 &gt; 12 . We add 2 HRSD17 point take account possibility measurement error . 3 . Outpatients inpatient antidepressant treatment deem appropriate treating clinician . 4 . Subjects 1885 year age . 5 . Participants general medical condition ( GMCs ) could conceivably physiologically cause depressive symptom receive treatment usual GMCs well MDD . Subjects medical contraindication preclude citalopram escitalopram treatment previously fail respond citalopram escitalopram exclude . In addition , patient schizophrenia , schizoaffective disorder , Bipolar I disorder excluded primary psychiatric condition require different initial treatment . Subjects currently antidepressant medication subtherapeutic result term depression management undergo medication taper discontinuation prior initiation citalopram escitalopram treatment . The subject closely monitor primary physician psychiatrist medication taper discontinuation phase . The medication taper leave upto treat physician 's psychiatrist 's discretion . Study subject safely tapered medication experience adverse effect taper exclude study . Study subject use antidepressant medication management nicotine dependence , chronic pain , migraine prophylaxis diagnose eligible study . Trazodone , Melatonin , Diphenhydramine may use rescue medication insomnia . Benzodiazepines may use treatment anxiety atomoxetine may use treatment attention deficit disorder . Study subject currently antipsychotic medication ( e.g. , typical atypical antipsychotic drug ) mood stabilize agent ( e.g. , lithium , carbamazepine , valproate , lamotrigine , gabapentin , anticonvulsant ) eligible study exception start quetiapine baseline . Subjects unable give inform consent exclude . Pregnant subject exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Depression</keyword>
	<keyword>Antidepressants</keyword>
</DOC>